Polymorphic forms of triazolopyrazine derivatives and method of preparing the same
AssigneeAbion Inc.
InventorsSeong-Hoon Jeong, Ki-Hyun Kim, Nam-Ah Kim
Life of this patent
Estimating the term…
Abstract
A crystalline modification of triazolopyrazine derivatives binds to a hepatocyte growth factor (HGF) to activate phosphorylation, thereby significantly inhibiting the activity of c-Met kinase triggering cell proliferation, migration, and formation of new blood vessels. Therefore, the compound of the present application may be effectively used for the treatment or prevention of various hyper proliferative disorders mediated by hyper proliferation activation of cells and excessive angiogenesis.
Claims30
A crystalline modification type I compound of the following Chemical Formula 1,
- wherein angles of 2θ representing X-ray diffraction (XRD) peaks of the crystalline modification include 3.35°, 6.75°, 7.94°, 10.40° and 12.37° (°2θ, ±0.1° using Cu-Kα1 radiation).
A crystalline modification type II compound of the following Chemical Formula 1,
- wherein angles of 2θ representing XRD peaks of the crystalline modification include 5.81°, 7.10°, 8.49°, 9.32°, 11.74°, 15.97°, and 16.45° (°2θ, ±0.1° using Cu-Kα1 radiation).
A crystalline modification type Ill compound of the following Chemical Formula 1,
- wherein angles of 2θ representing XRD peaks of the crystalline modification include 3.01°, 6.81°, 7.33°, and 12.28° (°2θ, ±0.1° using Cu-Kα1 radiation).
A crystalline modification type IV compound of the following Chemical Formula 1,
- wherein angles of 2θ representing XRD peaks of the crystalline modification include 5.81°, 6.93°, 8.42°, 9.43°, and 11.53° (°2θ, ±0.1° using Cu-Kα1 radiation).
A crystalline modification type V compound of the following Chemical Formula 1,
- wherein angles of 2θ representing XRD peaks of the crystalline modification include 8.71°, 9.67°, 11.36°, and 11.66° (°2θ, ±0.1° using Cu-Kα1 radiation).
A crystalline modification type VI compound of the following Chemical Formula 1,
- wherein angles of 2θ representing XRD peaks of the crystalline modification include 33.40°, 6.96°, 7.50°, 9.68°, and 12.50° (°2θ, ±0.1° using Cu-Kα1 radiation).
A crystalline modification type VII compound of the following Chemical Formula 1,
- wherein angles of 2θ representing XRD peaks of the crystalline modification include 3.09°, 6.31°, and 6.78° (°2θ, ±0.1° using Cu-Kα1 radiation).
Dependencies are inferred from the claim text.